Lin Shen, Zhi Peng, Changzheng Li, Linzhi Lu, Xiang Wang, Jun Zhang, Yanqiao Zhang, Ting Deng, Meili Sun, Dongyan Cai, Yin Jin, Hong Zong, Feng Ye, Huiting Xu, Mingjun Zhang, Jianzhi Liu, Dan Feng, Jianmin Fang. "Disitamab vedotin (DV) plus toripalimab (Tor) and chemotherapy (C)/trastuzumab (Tra) as first-line (1L) treatment of patients (pts) with HER2-expressing locally advanced or metastatic (la/m) gastric cancer.." Journal of Clinical Oncology, 2025. doi:10.1200/jco.2025.43.17_suppl.lba4012